Cargando…

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

The persistence or recurrence of minimal residual disease (MRD) after chemotherapy predicts relapse of B-cell acute lymphoblastic leukemia (B-ALL). CD19-directed chimeric antigen receptor T (CD19 CAR-T) cells have shown promising responses in B-ALL. However, their role in chemotherapy-refractory MRD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Wenyi, Wei, Yunxiong, Cao, Yaqing, Xiao, Xia, Li, Qing, Lyu, Hairong, Jiang, Yili, Zhang, Huan, Li, Xin, Jiang, Yanyu, Meng, Juanxia, Yuan, Ting, Zhu, Haibo, He, Xiaoyuan, Jin, Xin, Sun, Rui, Sui, Tao, Liu, Kaiqi, Zhao, Mingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571234/ https://www.ncbi.nlm.nih.gov/pubmed/33899130 http://dx.doi.org/10.1007/s00262-021-02941-4

Ejemplares similares

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL
por: He, Xiaoyuan, et al.
Publicado: (2019)

A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients
por: Lu, Wenyi, et al.
Publicado: (2022)

HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
por: Jin, Xin, et al.
Publicado: (2019)

Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome
por: Wei, Yunxiong, et al.
Publicado: (2021)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy
por: Wang, Jiaxi, et al.
Publicado: (2023)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
por: Jin, Xin, et al.
Publicado: (2023)

Infection Temperature Affects the Phenotype and Function of Chimeric Antigen Receptor T Cells Produced via Lentiviral Technology
por: Jin, Xin, et al.
Publicado: (2021)

Metagenomic Next-Generation Sequencing for Diagnostically Challenging Mucormycosis in Patients with Hematological Malignancies
por: Zhang, Meng, et al.
Publicado: (2022)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice
por: Jin, Xin, et al.
Publicado: (2018)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
por: Wang, Jia, et al.
Publicado: (2020)

The Value of Metagenomic Next-Generation Sequencing in Hematological Malignancy Patients with Febrile Neutropenia After Empiric Antibiotic Treatment Failure
por: Zhang, Meng, et al.
Publicado: (2022)

Overexpression of Both ERG11 and ABC2 Genes Might Be Responsible for Itraconazole Resistance in Clinical Isolates of Candida krusei
por: He, Xiaoyuan, et al.
Publicado: (2015)

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
por: Cao, Yaqing, et al.
Publicado: (2019)

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
por: Cao, Xinping, et al.
Publicado: (2023)

Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease
por: Helbig, Daniel, et al.
Publicado: (2020)

Allogeneic stem cell transplantation and minimal residual disease in patients with AML in first complete remission
por: Versluis, Jurjen, et al.
Publicado: (2018)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2018)

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
por: Lyu, Cuicui, et al.
Publicado: (2021)

A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient
por: Li, Xin, et al.
Publicado: (2022)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
por: Shiqi, Li, et al.
Publicado: (2023)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

CAR T cells remain during long-term cancer remission
por: Barnes, Katharine
Publicado: (2022)

Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2019)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Inherited GATA3 variant associated with positive minimal residual disease in childhood B‐cell acute lymphoblastic leukemia via asparaginase resistance
por: Li, Chunjie, et al.
Publicado: (2021)

Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma
por: Jiang, Duanfeng, et al.
Publicado: (2022)

Partial remission, residual symptoms, and relapse in depression
por: Paykel, E.S.
Publicado: (2008)

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Genome Variation Map of Domestic Qinghai-Tibet Plateau Yaks by SLAF-Seq Reveals Genetic Footprint during Artificial Selection
por: Li, Biao, et al.
Publicado: (2023)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
por: Liu, Jile, et al.
Publicado: (2023)

CAR‐T therapy as a consolidation in remission B‐ALL patients with poor prognosis
por: Yin, Zhichao, et al.
Publicado: (2022)

Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
por: Liu, Meijing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_47o4upo4djf3gtkmbufq9abtu5